Noticias de FATE_US

17/04/2026 FATE_US — MarketBeat

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Recommendation of "Hold" by Brokerages

16/04/2026 FATE_US — GlobeNewswire

Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at t

Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at…

16/04/2026 FATE_US — Stock Titan

Fate cell therapy study targets blood cancers without chemo

16/04/2026 FATE_US — MarketScreener

Fate Therapeutics Announces Data Presentation Of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate For The Broad Treatment Of Hematological Malignancies And Autoimmune Diseases Without The Need For Conditioning Chemotherapy

16/04/2026 FATE_US — MarketBeat

Fate Therapeutics Details Off-the-Shelf CAR T Progress in Lupus and Solid Tumors at Needham Conference

16/04/2026 FATE_US — Yahoo Finance

Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at t

Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at…

15/04/2026 FATE_US — Yahoo Finance

Fate Therapeutics Details Off-the-Shelf CAR T Progress in Lupus and Solid Tumors at Needham Conference

14/04/2026 FATE_US — openPR.com

NK Cell Therapy Market Is Booming Rapidly with Strong Demand

13/04/2026 FATE_US — Newser

Is Fate Therapeutics (FATE) Stock in a Selling Zone | FATE Q4 2025 Earnings: Fate Therapeutics Inc. tops EPS estimates, reports no revenue - Trading Community

13/04/2026 FATE_US — tayninh.gov.vn

FATE Q4 2025 Earnings: Fate Therapeutics Inc. tops EPS estimates, reports no revenue - Social Buy Zones

13/04/2026 FATE_US — newser.com

Is Fate Therapeutics (FATE) Stock in a Selling Zone | FATE Q4 2025 Earnings: Fate Therapeutics Inc. tops EPS estimates, reports no revenue - Miss Estimates

13/04/2026 FATE_US — laocai.gov.vn

FATE Q4 2025 Earnings: Fate Therapeutics Inc. tops EPS estimates, reports no revenue - Trend Analysis